339 research outputs found
Stock structure analysis of Nemipterus bipunctatus (Valenciennes, 1830) from three locations along the Indian coast
1888-1895Present study was done to identify the occurrence of various stocks of Nemipterus bipunctatus along the Indian coast, based on their body and skull shape morphometrics. Fish samples were collected from three locations along the Indian coast viz. Chennai along the East coast and Mumbai and Veraval on the West coast. Twenty truss distances from nine-point truss network of body and twenty-one truss distances from eleven-point truss network of the skull were measured from each fish sample. The canonical discriminant analysis showed that the truss distances belong to the anterior region and caudal peduncle of body and olfactory region of skull were significant in separating the fish stocks. The artificial neural network analysis revealed 91.4 % and 86.14 % well classification of the specimen, based on the truss distances of body and skull respectively. The results from the study indicated that there is a significant difference among the stocks of N. bipunctatus
Study to assess the prevalence of human leukocyte antigen-A*3101 allele among Indian epileptic patients and its influence on safety and efficacy of antiepileptic therapy
Background: The objective was to study the prevalence of human leukocyte antigen (HLA)-A*3101 allele among epileptic patients and to assess the safety and efficacy of antiepileptic therapy.Methods: 295 subjects were selected and divided into two groups, Group I had 192 epileptic patients and Group II had 103 normal healthy controls. After written informed consent, 30 ml of mouthwash sample was collected from each subject and DNA was extracted by standard salting-out technique and used for HLA-A*3101 genotyping by two-step nested allele-specific polymerase chain reaction amplification and agarose gel electrophoresis.Results: In Group I, 12 (6.25%) of the 192 patients were tested positive for HLA-A*3101 allele and all were taking carbamazepine (CBZ). Among them, 56 (30%) subjects had developed less severe adverse effects such as headache and giddiness, skin rashes and memory disturbances, and HLA-A*3101 was present in 8 of them while 136 had no adverse effects in which 4 of them were tested positive for the allele. In Group II, 3 (2.9%) of the 103 healthy controls were tested positive for the allele. No difference was found in response to antiepileptic therapy between allele positive and negative patients.Conclusion: The present study had shown that HLA-A*3101 is prevalent in 6.25% of the Indian epileptic population under study. The presence of this allele has a significant association with the development of mild cutaneous reactions like skin rashes. However, no difference was observed in allele positive patients in response to antiepileptic therapy in comparison with allele negative patients
PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value
Malignant astrocytomas comprise anaplastic astrocytoma (AA; grade III) and Glioblastoma (GBM; grade IV). GBM is the most malignant with a median survival of 10-12 months in patients. Using cDNA microarray based expression profiling of different grades of astrocytomas, we identified several fold increased levels of PBEF1 transcripts in GBM samples. Pre-B-cell colony enhancing factor 1 gene (PBEF1) encodes Nicotinamide phosphoribosyltransferase (NAmPRTase), which catalyses the rate limiting step in the salvage pathway of NAD metabolism in mammalian cells. Further validation using real time RT-qPCR on an independent set of tumor samples (n=91) and normal brain samples (n=9), GBM specific higher expression of PBEF1 was confirmed. Immunohistochemical staining for PBEF1 on a subset of the above samples largely reinforced our finding. We carried out ELISA analysis on serum samples of astrocytoma patients to determine whether this protein levels would correlate with the presence of tumor and tumor grade. PBEF1 serum levels were substantially elevated in many of the AA and GBM patients. Statistical analysis of these data indicates that in patients with astrocytoma, serum PBEF1 levels correlate with tumor grade and is highest in GBM. Immunohistochemical analysis of an independent set of 51 retrospective GBM cases with known survival data revealed that PBEF1 expression in the tumor tissue along with its co-expression with p53 was associated with poor survival. Thus, we have identified PBEF1 as a potential malignant astrocytoma serum marker and prognostic indicator among GBMs
Thermal photons in QGP and non-ideal effects
We investigate the thermal photon production-rates using one dimensional
boost-invariant second order relativistic hydrodynamics to find proper time
evolution of the energy density and the temperature. The effect of
bulk-viscosity and non-ideal equation of state are taken into account in a
manner consistent with recent lattice QCD estimates. It is shown that the
\textit{non-ideal} gas equation of state i.e behaviour
of the expanding plasma, which is important near the phase-transition point,
can significantly slow down the hydrodynamic expansion and thereby increase the
photon production-rates. Inclusion of the bulk viscosity may also have similar
effect on the hydrodynamic evolution. However the effect of bulk viscosity is
shown to be significantly lower than the \textit{non-ideal} gas equation of
state. We also analyze the interesting phenomenon of bulk viscosity induced
cavitation making the hydrodynamical description invalid. We include the
viscous corrections to the distribution functions while calculating the photon
spectra. It is shown that ignoring the cavitation phenomenon can lead to
erroneous estimation of the photon flux.Comment: 11 pages, 13 figures; accepted for publication in JHE
Ecopath modelling approach for the impact assessment of a small-scale coastal aquaculture system in Goa, India
In this study, the ecological impacts of introduction of cage aquaculture employing small cages integrating shellfish and finfish in coastal water bodies of Goa, situated in the west coast of India were analysed using Ecopath with Ecosim model. A multispecies cage aquaculture system incorporating Lutjanus argentimaculatus, Etroplus suratensis and Perna viridis was established in an estuarine ecosyste
Beneficial impacts of biochar as a potential feed additive in animal husbandry
In the last decade, biochar production and use have grown in popularity. Biochar is comparable to charcoal and activated charcoal because it is a pyrogenic carbonaceous matter made by pyrolyzing organic carbon-rich materials. There is a lack of research into the effects of adding biochar to animal feed. Based on the reviewed literature, including its impact on the adsorption of toxins, blood biochemistry, feed conversion rate, digestion, meat quality, and greenhouse gas emissions, adding biochar to the diet of farm animals is a good idea. This study compiles the most important research on biochar's potential as a supplement to the diets of ruminants (including cows and goats), swine, poultry, and aquatic organisms like fish. Biochar supplementation improves animal growth, haematological profiles, meat, milk and egg yield, resistance to illnesses (especially gut pathogenic bacteria), and reduced ruminant methane emission. Biochar's strong sorption capacity also helps efficiently remove contaminants and poisons from the animals' bodies and the farm surroundings where they are raised. Animal farmers are predicted to make greater use of biochar in the future. Biochar could potentially be of value in the healthcare and human health fields; hence research into this area is encouraged. The present review highlights the potential benefits of biochar as an additive to animal feed and demonstrates how, when combined with other environmentally friendly practices, biochar feeding can extend the longevity of animal husbandry
Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis
Purpose: Current methods of classification of astrocytoma based on histopathologic methods are often subjective and less accurate. Although patients with glioblastoma have grave prognosis, significant variability in patient outcome is observed. Therefore, the aim of this study was to identify glioblastoma diagnostic and prognostic markers through microarray analysis. Experimental Design: We carried out transcriptome analysis of 25 diffusely infiltrating astrocytoma samples [WHO grade II - diffuse astrocytoma, grade III - anaplastic astrocytoma, and grade IV - glioblastoma (GBM)] using cDNA microarrays containing 18,981 genes. Several of the markers identified were also validated by real-time reverse transcription quantitative PCR and immunohistochemical analysis on an independent set of tumor samples (n = 100). Survival analysis was carried out for two markers on another independent set of retrospective cases (n = 51). Results: We identified several differentially regulated grade-specific genes. Independent validation by real-time reverse transcription quantitative PCR analysis found growth arrest and DNA-damage-inducible α (GADD45α) and follistatin-like 1 (FSTL1) to be up-regulated in most GBMs (both primary and secondary), whereas superoxide dismutase 2 and adipocyte enhancer binding protein 1 were up-regulated in the majority of primary GBM. Further, identification of the grade-specific expression of GADD45α and FSTL1 by immunohistochemical staining reinforced our findings. Analysis of retrospective GBM cases with known survival data revealed that cytoplasmic overexpression of GADD45α conferred better survival while the coexpression of FSTL1 with p53 was associated with poor survival. Conclusions: Our study reveals that GADD45α and FSTLI are GBM-specific whereas superoxide dismutase 2 and adipocyte enhancer binding protein 1 are primary GBM-specific diagnostic markers. Whereas GADD45α overexpression confers a favorable prognosis, FSTL1 overexpression is a hallmark of poor prognosis in GBM patients
Flow in heavy-ion collisions - Theory Perspective
I review recent developments in the field of relativistic hydrodynamics and
its application to the bulk dynamics in heavy-ion collisions at the
Relativistic Heavy- Ion Collider (RHIC) and the Large Hadron Collider (LHC). In
particular, I report on progress in going beyond second order relativistic
viscous hydrodynamics for conformal fluids, including temperature dependent
shear viscosity to entropy density ratios, as well as coupling hydrodynamic
calculations to microscopic hadronic rescattering models. I describe
event-by-event hydrodynamic simulations and their ability to compute higher
harmonic flow coefficients. Combined comparisons of all harmonics to recent
experimental data from both RHIC and LHC will potentially allow to determine
the desired details of the initial state and the medium properties of the
quark-gluon plasma produced in heavy-ion collisions.Comment: 8 pages, Invited plenary talk at the 22nd International Conference on
Ultrarelativistic Nucleus-Nucleus Collisions (Quark Matter 2011), May 23-28
2011, Annecy, Franc
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial
Trilaciclib is an intravenous CDK4/6 inhibitor administered prior to chemotherapy to
preserve haematopoietic stem and progenitor cells and immune system function from
chemotherapy-induced damage (myelopreservation). The effects of administering trilaciclib prior to carboplatin, etoposide and atezolizumab (E/P/A) were evaluated in a
randomised, double-blind, placebo-controlled Phase II study in patients with newly
diagnosed extensive-stage small cell lung cancer (ES-SCLC) (NCT03041311). The primary endpoints were duration of severe neutropenia (SN; defined as absolute neutrophil count <0.5 × 109 cells per L) in Cycle 1 and occurrence of SN during the
treatment period. Other endpoints were prespecified to assess the effects of trilaciclib on additional measures of myelopreservation, patient-reported outcomes,
antitumour efficacy and safety. Fifty-two patients received trilaciclib prior to E/P/A
and 53 patients received placebo. Compared to placebo, administration of trilaciclib
resulted in statistically significant decreases in the mean duration of SN in Cycle
1 (0 vs 4 days; P < .0001) and occurrence of SN (1.9% vs 49.1%; P < .0001), with
additional improvements in red blood cell and platelet measures and health-related
quality of life (HRQoL). Trilaciclib was well tolerated, with fewer grade ≥3 adverse
events compared with placebo, primarily due to less high-grade haematological toxicity. Antitumour efficacy outcomes were comparable. Administration of trilaciclib vs
placebo generated more newly expanded peripheral T-cell clones (P = .019), with significantly greater expansion among patients with an antitumour response to E/P/A
(P = .002). Compared with placebo, trilaciclib administered prior to E/P/A improved
patients' experience of receiving treatment for ES-SCLC, as shown by reduced
myelosuppression, and improved HRQoL and safety profiles
- …